Molecular architecture of tumor suppressor p53

Current Topics in Medicinal Chemistry

Volumn 8, Issue 15, 2008, Pages 1327-1334

  Viadiu, Hector ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

DNA binding domain; NMR; p53; Regulatory domain; Tetramerization domain; Transactivation domain; Transcription factor; X ray crystallography

Indexed keywords

PROTEIN P53;

APOPTOSIS; CELL CYCLE ARREST; DNA BINDING; DNA DAMAGE; DNA HELIX; DNA SEQUENCE; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; STRUCTURE ANALYSIS; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; DNA; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 57849103962     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608786141160     Document Type: Review

References (54)

1. Toledo, F.; Wahl. G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 2006, 6, 909-23.
2. Joerger, A.C.; Fersht. A.R. Structural Vology of the tumor suppressor p53. Annu. Rev. Biochem. 2008, 77, 557-82.
3. Olivier, M.; Eeles, R. Hollstein, M.; Khan, M.A.; Harris, C.C.; Hainaut. P.The IARC TP53 database: New online mutation analysis and recommendations to users. Hum. Mutat. 2002, 19, 607-14.
4. Bell, S.; Klein, C.; Muller, L.; Hansen, S.;Buchner. J. p53 contains large unstructured regions in its native state. J. Mol. Biol. 2002, 322, 917-27.
5. Cho, Y.; Gorina, S.; Jeffrey, P.D.; Pavletich. N.P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994, 265, 346-55.
6. Clore, G.M.; Omichinski, J.G. Sakaguchi, K.; Zambrano, N.; Sakamoto, H.; Appella, E.; Gronenborn. A.M. High-resolution structure of the oligornerization domain of p53 by multidimensional NMR. Science 1994 265, 386-91.
7. Clore, G.M.; Ernst, J.; Clubb, R.; Omichinski, J.G.; Kennedy, W.M.; Sakaguchi, K.; Appella, E.; Gronenborn. A.M. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat. Struct. Biol. 1995, 2 321-33.
8. Lee, W.; Harvey, T.S.; Yin, Y.; Yau, P.; Litchfield, D.; Arrowsmith. C.H. Solution structure of the tetrameric minimum transforming domain of p53. Nat. Struct. Biol. 1994, 1, 877-90.
9. Jeffrey, P.D.; Gorina, S.; Pavletich. N.P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 1995, 267, 1498-502.
10. Kussie, P.H.; Gorina, S.; Mirechal, V.; Elenbaas, B.; Moreau, J.; Levine, AJ.; Pavletich. N.P.Structure of the MDM2 oncoprotei bound to the p53 tumor suppressor transactivation domain. Science 1996, 274, 948-53.
11. Rustandi, R.R.; Baldisseri, D.M.; Weber. DJ i Structure of the negative regulatory domain of p53 bound to S100B(betabeta). Nat. Struct. Biol. 2000, 7, 570-4.
12. Avalos, J.L.; Bever, K.M.; Wolberger. C. Mechanism of sirtuin inhibition by nicotinamide: Altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol. Cell 2005, 17, 855-68.
13. Lowe, E.D.; Tews, I.; Cheng, K.Y.; Brown, N.R.; Gul, S.;. Noble, M.E.; Gamblin, S.J.; Johnson. L.N. Specificity determinants of recruitment peptides bound to phospho-CDK2/cychn A Biochemistry 2002, 41, 15625-34.
14. Dawson, R.; Muller, L.; Delmer, A.; Klein, C.; Kessler, H.; Buchner. J. The N-terminal domain of p53 is natively unfolded. J. Mol. Biol. 2003, 332, 1131-41.
15. Harms, K.L.; Chen. X. The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differ. 2006, 13, 890-7.
16. Scoumanne, A.; Harms, K.L; Chen. X. Structural basis for gene activation by p53 family members. Cancer Biol. Ther. 2005, 4, 1178-85.
17. Bochkareva, E.; Kaustov, L.; Ayed, A.; Yi, G.S.; Lu, Y.; Pineda-Lucena, A.; Liao, J.C.; Okorokov, A.L.; Milner, J.; Arrowsmith, C.H.; Bochkarev. A. Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc. Natl. Acad. Sci. USA 2005, 102, 15412-7.
18. Zhao, K.; Chai, X.; Johnston, K.; Clements, A.; Marmorstein. R. Crystal structure of the mouse p53 core DNA-binding domain at 2.7 A resolution. J. Biol. Chem. 2001, 276, 12120-7.
19. el-Deiry, W.S.; Kern, S.E. Pietenpol, J.A.; Kinzler, K.W.; Vogelstein. P. Definition of a consensutbieding site for p53. Nat. Genet. 1992, 1 45-9.
20. Kitayner, M.; Rozenberg, H.; Kessler, N.; Rabinovich, D.; Shaulov, L.; Haran, T.E.; Shakked. Z. Structural basis of DNA recognition by p53 intramers. Mol. Cell. 2006, 22, 741-53.
21. Joerger, A.C.; Aflen, M.D.; Fersht. A.R. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J. Biol. Chem. 2004, 279, 1291-6.
22. Joerger, A.C.; Ang, H.C.; Fersht. A.R. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc. Natl. Acad. Sci. USA 2006, 103 15056-61.
23. Joerger, A.C.; Ang, H.C.; Veprintsev, D.B.; Blair, C.M.; Fersht. A.R. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J. Biol. Chem. 2005, 280, 16030-7.
24. Clore, G.M.; Omichinski, J.G.; Sakaguchi, K.; Zambrano, N.; Sakamoto, H.; Appella, E.; Gronenborn. A.M. Interhelical angles in the solution structure of the oligomerization domain of p53: Correction. Science 1995, 267, 1515-6.
25. McCoy, M.; Stavridi, E.S.; Waterman, J.L.; Wieczorek, A.M.; Opella, S.J.; Halazonetis. T.D. Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain. EMBO J. 1997, 16, 6230-6.
26. Davison, T.S.; Nie, X.; Ma, W.; Lin, Y.; Kay, C.; Beachimol, S.; Arrowsmith. C.H. Structure and functionality of a designed p53 dimer. J. Mol. Biol. 2001, 307, 605-17.
27. Avalos, J.L.; Celic, I. Muhammad, S.; Cosgrove, M.S.; Boeke, J.D.; Wolberger. C. Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol. Cell 2002, 19, 523-35.
28. Mujtaba, S.; He, Y.; Zeng, L.; Yan, S.; Plotnikova, O.; Sachchidanand; Sanchez, R.; Zeleznik-Le, N.J.; Ronai, Z.; Zhou, M.M. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol. Cell. 2004, 13, 251-63.
29. Okorokov, A.L.; Sherman, M.B.; Plisson, C.; Grinkevich, V.; Sigmundsson, K.; Selivanova, G.; Milner, J.; Orlova. E.V. The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. EMBO J. 2006, 25, 5191-200.
30. Tidow, H.; Melero, R. Mylonas, E.; Freund, S.M.; Grossmann, J.G.; Carazo, J.M.; Svergun, D.I.; Valle, M.; Fersht. A.R.; Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc. Natl. Acad. Sci. USA 2007, 104, 12324-9.
31. Rosal, R.; Pincus, M.R.; Brandt-Rauf, P.W.; Fine, R.L.; Michl, J.; Wang. H. NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells. Biochemistry 2004, 43, 1954-61.
32. Grasberger, B.L.; Lu, T.; Schubert, C.; Parks, D.J.; Carver, T.E.; Koblish, H.K.; Cummings, M.D.; LaFrance, L.V.; Milkiewicz, K.L.; Calvo, R.R.; Maguire, D.; Lattanze, J.; Franks, C.F.; Zhao, S.; Ramachandren, K.; Bylebyl, G.R.; Zhang, M.; Manthey, C.L.; Petrella, E.C.; Pantoliano, M.W.; Deckman, I.C.; Spurlino, J.C.; Maroney, A.C.; Tomczuk, B.E.; Molloy, C.J.; Bone. R.F. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. 2005, 48, 909-12.
33. Di Lello, P.; Jenkins, L.M.; Jones, T.N.; Nguyen, B.D; Hara, T.; Yamaguchi, H.; Dikeakos, J.D.; Appella, E.; Legault, P.; Omichinski. J.G.; Structure of the Tfb1/p53 complex: Insights into the interaction between the p6ZfMl subunit of TFl1H and the activation domain of p53. Mol. Cell 2006, 22, 731-40.
34. Sakurai, K.; Schubert, C.; Kahne. D.; Crystallographic analysis of an 8-mer p53 peptide analogue complexed with MDM2. J. Am. Chem. Soc. 2006, 128, 11000-1.
35. Popowicz, G.M.; Czama, A.; Rothweiler, U.; Sszwagierezak, A.; Krajewsld, M.; Weber, L.; Holak. T.A Molecular Basis for the Inhibition of p53 by Mdmx. Cell Cycle 2007, 6.
36. Gorina, S.; Pavletich. N.P. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 1996, 274, 1001-5.
37. Joo, W.S.; Jeffrey, P.D. Cantor, S.B.; Finnin, M.S.; Livingston, D.M.; Pavletich. N.P. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Genes. Dev. 2002, 16, 583-93.
38. Derbyshire, D.J.; Basu, B.P.; Serpell, L.C.; Joo, W.S.; Date, T.; Iwabuchi, K.; Doherty. A.J. Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. EMBO J. 2002, 21, 3863-72.
39. Huyen, Y.; Jeffrey, P.D.; Derry, W.B.; Rothman, J.H.; Pavletich, N.P.; Stavridi, E.S.; Halazonetis. T.D. Structural differences in the DNA binding domains of human p53 and its C. elegans ortholog Cep-1. Structure 2004, 12, 1237-43.
40. Canadillas, J.M.; Tidow,; Freund, S.M.; Rutherford, T.J.;. Ang, H.C.; Fersht. A.R. Solution structure of p53 core domain: Structural basis for its instability. Proc. Natl. Acad. Sci USA 2006, 103, 2109-14.
41. Ho, W.C.; Fitzgerald, M.X.; Marmorstein. R. Structure of the p53 core domain dimer bound to DNA. J. Biol. Chem. 2006, 281, 20494-502.
42. Lilyestrom, W.; Klein, M.G.; Zhang, R; Joachimiak, A.; Chen. X.S. Crystal structure of SV40 large T-antigen bound to p53: Interplay between a viral oncoprotein and a cellular tumor suppressor. Genes. Dev. 2006, 20, 2373-82.
43. Ho, W.C.; Luo, C.; Zhao, K.; Chai, X.; Fitzgerald, M.X.; Marmorstein. R. High-resolution structure of the p53 core domain: Implications for binding small-molecule stabilizing compounds. Acta. Crystallogr D. Biol. Crystallogr. 2006, 62, 1484-93.
44. Wang, Y.; Rosengarth, A.; Luecke. H.; Structure of the human p53 core domain in the absence of DNA. Acta. Crystallogr D. Biol. Crystallogr 2007, 63, 276-81.
45. Kwon, E.; Kim, D.Y.; Suh, S.W.; Kim, K.K. Crystal structure of the mouse p53 core domain in zinc-free state. Proteins 2008, 70, 280-3.
46. Tu, C.; Tan, Y.H.; Shaw, G.; Zhou, Z.; Bai, Y.; Luo, R.; Ji, X.; Impact of low-frequency hotspot mutation R282Q on the structure of p53 DNA-binding domain as revealed by crystallography at 1.54 angstroms resolution. Acta Crystallogr. D Biol. Crystallogr. 2008, 64, 471-7.
47. Mittl, P.R.; Chene, P.; Grutter. M.G. Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template. Acta Crystallogr. D. Biol. Crystallogr. 1998, 54, 86-9.
48. Kuszewski, J.; Gronenbom, A.M.; Clore. G.M.; Improving the Packing and Accuracy of NMR Structure with a Pseudopotential for the Radius of Gyration. J. Am. Chem. Soc. 1999, 121, 2337-2338
49. Poux, A.N.; Marmorstein. R. Molecular basis for Gcn5/PCAF histone acetyltransferase selectivity for histone and nonhistone substrates. Biochemistry 2003, 42, 14366-74.
50. Chuikov, S.; Kurash, J.K.; Wilson, J.R.; Xiao, B.; Justin, N.; Ivanov, G.S.; McKinney, K.; Tempst, P.; Prives, C.; Gamblin, S.J.; Barlev, N.A.; Reinberg. D. Regulation of p53 activity through lysine methylation. Nature 2004, 432, 353-60.
51. Hu, M.; Gu, L. Li, M.; Jeffrey, P.D.; Gu, W.; Shi. Y. Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: Implications for the regulation of the p53-MDM2 pathway. PLoS Biol. 2006, 4, e27.
52. Sheng, Y.; Saridakis, V.; Sarkari, F.; Duan, S.; Wu, T.; Arrowsmith, C.H.; Frappier. L. Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat. Struct. Mol. Biol. 2006, 13, 285-91.
53. Cosgrove, M.S.; Bever, K. Avalos, J.L.; Muhammad, S.; Zhang, X.; Wolberger. C. The structural basis of sirtuin substrate affinity. Biochemistry 2006, 45, 7511-21.
54. Hoff, K.G.; Avalos, J.L.; Sens, K.; Wolberger C. Insights into the sirtuin mechanism from ternary complexes containing NAD+ and acetylated peptide. Structure 2006, 14, 1231-40.